The World Health Organization endorsed lenacapavir for HIV prevention during the International AIDS Conference in Kigali, Rwanda. This recommendation follows the Food and Drug Administration's approval of the drug approximately one month earlier. The injectable medication requires administration only twice annually, representing a significant advancement over existing prevention methods. Clinical trials demonstrated that lenacapavir provides nearly complete protection against HIV infection. The drug received initial approval in 2022 for treating specific HIV infections before researchers explored its preventive applications.
Dr. Meg Doherty from WHO's Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes outlined two primary recommendations during a news briefing. The organization advocates for lenacapavir as an additional prevention option for at-risk populations within comprehensive prevention programs. WHO also endorses rapid diagnostic testing, particularly home-based tests, for individuals beginning or discontinuing pre-exposure prophylaxis treatment. These guidelines aim to enhance real-world implementation of HIV prevention strategies. The organization collaborates with countries and partners to facilitate adoption of these new protocols.
The biannual injection schedule offers advantages for individuals who struggle with medication adherence or prefer fewer clinical appointments. Lenacapavir represents an alternative to existing pre-exposure prophylaxis options like Truvada pills or Apretude injections. The medication proves safe for pregnant and breastfeeding women, expanding its potential user base. However, funding concerns threaten global HIV prevention efforts, with international assistance supporting 80 percent of programs in developing nations. Recent cuts to American foreign aid programs raise alarm about future HIV prevention capabilities worldwide.
Dr. Meg Doherty from WHO's Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes outlined two primary recommendations during a news briefing. The organization advocates for lenacapavir as an additional prevention option for at-risk populations within comprehensive prevention programs. WHO also endorses rapid diagnostic testing, particularly home-based tests, for individuals beginning or discontinuing pre-exposure prophylaxis treatment. These guidelines aim to enhance real-world implementation of HIV prevention strategies. The organization collaborates with countries and partners to facilitate adoption of these new protocols.
The biannual injection schedule offers advantages for individuals who struggle with medication adherence or prefer fewer clinical appointments. Lenacapavir represents an alternative to existing pre-exposure prophylaxis options like Truvada pills or Apretude injections. The medication proves safe for pregnant and breastfeeding women, expanding its potential user base. However, funding concerns threaten global HIV prevention efforts, with international assistance supporting 80 percent of programs in developing nations. Recent cuts to American foreign aid programs raise alarm about future HIV prevention capabilities worldwide.
